Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD6738 + Durvalumab in Refractory Biliary Tract Cancer
NCT04298008Phase 2Recruiting
- Sponsor
- Seoul National University Hospital
- Start
- Jun 2020
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ceralasertib in biliary tract cancer (BTC), sponsored by Seoul National University Hospital. Started Jun 2020; status: recruiting.
02
Drugs
ceralasertib
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT04298008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04298008.